On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
BioAgilytix’s global team of highly experienced scientific and QA professionals deliver world-leading science, proven data integrity, and deep regulatory expertise to support all phases of large molecule global studies. Today we provide comprehensive GxP services to innovators all over the world, including many of the top global pharmaceutical and biotech companies.
Our cutting edge bioanalytical lab has evolved the model for partnership in large molecule bioanalysis to benefit our customers and the patients they serve. Don’t allow a promising drug candidate or clinical study to stall out due to a lack of expertise or resources. BioAgilytix provides best-in-class bioanalytical capabilities that are needed to address the most challenging biomarker, immunogenicity, PK and cell-based assay requirements.
BioAgilytix is singularly committed to providing you with the scientific and regulatory expertise needed to overcome bioanalytical complexities and avoid quality pitfalls in every phase of development. Put your large molecule therapeutics in our expert hands, and we will give you the confidence of the most accurate, precise, and comprehensive high-quality scientific processes and data – with results that are delivered right on time, and right the first time.